Legal Representation
Attorney
Jayme M. Torelli
USPTO Deadlines
Next Deadline
98 days remaining
NOA E-Mailed - SOU Required
Due Date
April 22, 2026
Extension Available
Until October 22, 2026
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Sep 20, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Sep 19, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Sep 19, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Sep 19, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 13, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Mar 13, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Mar 12, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Mar 12, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Oct 22, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Aug 27, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Aug 27, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Aug 7, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Jul 25, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 24, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 24, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 24, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 9, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 9, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 9, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 9, 2024 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 29, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 10, 2024 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations for the treatment and prevention of motion sickness; Pharmaceutical preparations for the treatment and prevention of cravings for opioid substances or opiate substances; Pharmaceutical preparations for the treatment and prevention of nausea; Pharmaceutical preparations for the treatment and prevention of vomiting; Pharmaceutical preparations for the treatment and prevention of substance dependence; Pharmaceutical preparations for the treatment and prevention of anxiety; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by an over-expression of the neuropeptide known as substance P; Pharmaceutical preparations for the treatment and prevention of diseases, disorders, or conditions caused by overstimulation of the neurokinin-1 (NK-1) receptor; Pharmaceutical preparations for the treatment of pruritus; Pharmaceutical preparations for the treatment of atopic dermatitis; Pharmaceutical preparations for the treatment of pain; Pharmaceutical preparations for the treatment of bipolar disorder; Pharmaceutical preparations for the treatment of schizophrenia; Pharmaceutical preparations for the treatment of bile acid diarrhea; Pharmaceutical preparations for the treatment of tyrosine kinase inhibitor (TKI)-induced diarrhea; Pharmaceutical preparations for the treatment of gastroparesis; Pharmaceutical preparations for the treatment of COVID-19; Pharmaceutical preparations for the treatment of inflammatory lung injury (ILI); Pharmaceutical preparations for the treatment of acute respiratory distress syndrome (ARDS); Pharmaceutical preparations for the treatment of social anxiety disorder; Pharmaceutical preparations for the treatment of performance anxiety; Pharmaceutical preparations for the treatment of public speaking anxiety; Pharmaceutical preparations for the treatment of circadian rhythm disorders; Pharmaceutical preparations for the treatment of jet lag disorder; Pharmaceutical preparations for the treatment of insomnia; Pharmaceutical preparations for the treatment of Delayed Sleep Phase Disorder (DSPD); Pharmaceutical preparations for the treatment of non-24 hour sleep-wake disorder; Pharmaceutical preparations for the treatment of Smith-Magenis Syndome; Pharmaceutical preparations for the treatment of nighttime sleep disturbances in patients with Smith-Magenis Syndrome (SMS); Pharmaceutical preparations for the treatment of major depressive disorder (MDD); Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the treatment of multiple myeloma; Pharmaceutical preparations for the treatment of Charcot-Marie-Tooth disease; Pharmaceutical preparations for the treatment of hematologic malignancies; Pharmaceutical preparations for treating epidermal problems; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology
Classification
International Classes
005